Investigator
Theageneio General Hospital
Incidence, characteristics and outcome of therapy‐related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly‐ADPribose polymerase inhibitors: A cancer center experience
AbstractPoly(ADP‐ribose) polymerase inhibitors (PARPi) target the DNA repair pathways and have been established in epithelial ovarian cancer (EOC) as maintenance therapy inducing prolonged survival. However, recently published data showed that PARPi may increase the risk of therapy‐related myeloid neoplasms (t‐MN) including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Herein, we investigated the incidence, characteristics, and management of t‐MN among EOC patients after exposure to PARPi in a Greek Cancer Center. We analyzed 112 consecutive EOC patients treated with PARPi with a median age of 58 years (range 28–84). Olaparib and Niraparib were used in 90 and 22 patients, respectively. The median number of previous chemotherapy lines and duration of treatment with PARPi were 2 (range 1–9) lines and 12 (range 2–24) months, respectively. The incidence of t‐MN among patients treated with PARPi was 3.57% (4/112). Patients with t‐MN were distributed as follows: t‐MDS: 1, t‐MDS/AML: 1, t‐AML: 2. We observed adverse cytogenetic features in t‐MN patients leading to dismal prognosis. In conclusion, in accordance with previous real‐world reports, we confirm a notable risk for t‐MN in EOC patients treated with PARPi. As PARPi are an emerging therapy for many neoplasms, there is an unmet clinical need to identify patients who are considered at high risk for developing t‐MN post‐therapy with PARPi in order to introduce potential preventive strategies.
Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
Abstract Involvement of female genital track (FGT) by diffuse large B cell lymphoma (DLBCL) represents an extremely rare diagnosis. Especially data regarding early‐stage disease (i.e., IE, IIE) is very limited. Importantly, previous studies showed controversial results about the risk of central nervous system (CNS) relapse in this entity. Herein, we describe one of the largest reported real‐world series of patients with early‐stage FGT DLBCL aiming to investigate the clinicopathological characteristics, response to therapy and survival outcomes in the era of immunochemotherapy. We analyzed 21 consecutive patients with biopsy proven DLBCL from uterus or ovary classified as stage IE or IIE out of 1905 newly diagnosed DLBCL patients (1.1%). Uterine and ovarian localization was observed in 14 and seven patients, respectively. Median age was 66 years (range 33–96); 9/21 (43%) were <55 years. Regarding Cell of Origin DLBCL subtype, Germinal Center B‐cell subtype was found in seven patients, non‐GCB in 10 and non‐classified in 4 patients. Median follow‐up was 57 months and 5‐year overall survival, lymphoma specific survival and Freedom from Progression were 78%, 89% and 90%, respectively. There was no correlation of patients' characteristics with survival parameters. Interestingly, none of the patients experienced CNS relapse. Our results indicate that localized FGT DLBCL exhibits a good prognosis and may not increase the risk for secondary CNS involvement.
